{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:51:25Z","timestamp":1782845485151,"version":"3.54.5"},"reference-count":66,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Public Health Surveill"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Both COVID-19 and pregnancy are associated with hypercoagulability. Due to the increased risk for thrombosis, the United States National Institute of Health\u2019s recommendation for prophylactic anticoagulant use for pregnant patients has expanded from patients hospitalized for severe COVID-19 manifestation to all patients hospitalized for the manifestation of COVID-19 (no guideline: before December 26, 2020; first update: December 27, 2022; second update: February 24, 2022-present). However, no study has evaluated this recommendation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to characterize prophylactic anticoagulant use among hospitalized pregnant people with COVID-19 from March 20, 2020, to October 19, 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study in large US health care systems across 7 states. The cohort of interest was pregnant patients who were hospitalized with COVID-19, without previous coagulopathy or contraindication to anticoagulants (n=2767). The treatment group consisted of patients prescribed prophylactic dose anticoagulation between 2 days before and 14 days after COVID-19 treatment onset (n=191). The control group was patients with no anticoagulant exposure between 14 days before and 60 days after COVID-19 treatment onset (n=2534). We ascertained the use of prophylactic anticoagulants with attention to the updates in guidelines and emerging SARS-CoV-2 variants. We propensity score matched the treatment and control group 1:1 on the most important features contributing to the prophylactic anticoagulant administration status classification. Outcome measures included coagulopathy, bleeding, COVID-19\u2013related complications, and maternal-fetal health outcomes. Additionally, the inpatient anticoagulant administration rate was validated in a nationwide population from Truveta, a collective of 700 hospitals across the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall administration rate of prophylactic anticoagulants was 7% (191\/2725). It was lowest after the second guideline update (no guideline: 27\/262, 10%; first update: 145\/1663, 8.72%; second update: 19\/811, 2.3%; P&lt;.001) and during the omicron-dominant period (Wild type: 45\/549, 8.2%; Alpha: 18\/129, 14%; Delta: 81\/507, 16%; and Omicron: 47\/1551, 3%; P&lt;.001). Models developed on retrospective data showed that the variable most associated with the administration of inpatient prophylactic anticoagulant was comorbidities prior to SARS-CoV-2 infection. The patients who were administered prophylactic anticoagulant were also more likely to receive supplementary oxygen (57\/191, 30% vs 9\/188, 5%; P&lt;.001). There was no statistical difference in a new diagnosis of coagulopathy, bleeding, or maternal-fetal health outcomes between those who received treatment and the matched control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most hospitalized pregnant patients with COVID-19 did not receive prophylactic anticoagulants across health care systems as recommended by guidelines. Guideline-recommended treatment was administered more frequently to patients with greater COVID-19 illness severity. Given the low rate of administration and differences between treated and untreated cohorts, efficacy could not be assessed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/45586","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T15:17:46Z","timestamp":1686669466000},"page":"e45586","source":"Crossref","is-referenced-by-count":2,"title":["Adoption of a National Prophylactic Anticoagulation Guideline for Hospitalized Pregnant Women With COVID-19: Retrospective Cohort Study"],"prefix":"10.2196","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4193-8623","authenticated-orcid":false,"given":"Yeon-Mi","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8119-6724","authenticated-orcid":false,"given":"Samantha","family":"Piekos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7689-1298","authenticated-orcid":false,"given":"Tanya","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7158-3678","authenticated-orcid":false,"given":"Leroy","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6103-7606","authenticated-orcid":false,"given":"Jennifer","family":"Hadlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2021.12.010"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0343-0"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050354"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa623"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14850"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14854"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31209-5"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00762-9"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.121.316101"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01634-2020"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-10-200511150-00006"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.277"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.02921.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103893"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-022-00998-0"},{"key":"ref16","unstructured":"Hospitalization and Blood ClotsCenters for Disease Control and Prevention Internet20222022-12-03https:\/\/www.cdc.gov\/ncbddd\/dvt\/hospitalization-infographic.html"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00665-7"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2021.045"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/17539447211053470"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12462"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100639"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215383"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020203557"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069590"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.819318"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X21995566"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.08.004"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/516420"},{"key":"ref29","unstructured":"NIH COVID-19 Treatment GuidelinesNational Institute of Health2023-06-20https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antithrombotic-therapy\/"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.28008"},{"key":"ref31","unstructured":"BauerKAUse of anticoagulants during pregnancy and postpartumUpToDate20222023-06-20Waltham, MAUpToDatehttps:\/\/www.uptodate.com\/contents\/use-of-anticoagulants-during-pregnancy-and-postpartum"},{"key":"ref32","unstructured":"Geospatial Research, Analysis, and Services Program. CDC\/ATSDR Social Vulnerability IndexCenters for Disease Control and Prevention\/ Agency for Toxic Substances and Disease Registry20202022-12-07https:\/\/www.atsdr.cdc.gov\/placeandhealth\/svi\/data_documentation_download.html"},{"key":"ref33","unstructured":"U.S. Department of Agriculture\u2019s Economic Research Service (ERS)Rural-Urban Commuting Area Codes20102022-12-07https:\/\/www.ers.usda.gov\/data-products\/rural-urban-commuting-area-codes\/"},{"key":"ref34","unstructured":"COVID Data TrackerCenters for Disease Control and Prevention2022-11-15https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions"},{"key":"ref35","unstructured":"Symptoms of COVID-19Centers for Disease Control and Prevention20222023-04-25https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1109\/LSP.2014.2337313"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00105-8"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000005147"},{"key":"ref40","unstructured":"LundbergSMLeeSIA unified approach to interpreting model predictions2017NIPS'17: Proceedings of the 31st International Conference on Neural Information Processing SystemsDecember 4 - 9, 2017Long Beach California USARed Hook, NY, United StatesCurran Associates Inc"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.060"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1109\/EMBC48229.2022.9871333"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq224"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.4300\/JGME-D-12-00156.1"},{"key":"ref46","unstructured":"Truveta's health system membersTruveta20222023-03-30https:\/\/www.truveta.com\/members\/"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1074775"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.14744\/scie.2020.86548"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2020.100134"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15462"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.08.041"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n311"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.11788"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-009495"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7047e1"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2021.08.019"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2393-13-129"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.09.602"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-021-00998-x"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6665573"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100333"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.617976"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.12.1036"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(21)00250-8"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1101\/2022.08.12.22278727"},{"key":"ref66","unstructured":"COVID19 Maternity Inpatient Anticoagulant PublicGitHub2023-07-03https:\/\/github.com\/Hadlock-Lab\/COVID19_Maternity_Inpatient_Anticoagulant"}],"container-title":["JMIR Public Health and Surveillance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publichealth.jmir.org\/2023\/1\/e45586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:51:18Z","timestamp":1782841878000},"score":1,"resource":{"primary":{"URL":"https:\/\/publichealth.jmir.org\/2023\/1\/e45586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":66,"URL":"https:\/\/doi.org\/10.2196\/45586","relation":{"has-preprint":[{"id-type":"doi","id":"10.2196\/preprints.45586","asserted-by":"object"}]},"ISSN":["2369-2960"],"issn-type":[{"value":"2369-2960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]}}}